Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. 1987

L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze

In this study, it has been shown that in 21 patients with AML the dCyd kinase and dCyd deaminase activities correspond closely to the clinical response to ara-C remission induction therapy. Patients with primary disease were treated with a conventional-dose ara-C regimen whereas nonresponders and relapsed patients followed an ID ara-C regimen (1 g/m2 X 12). Of these 21 patients (11 with primary disease and ten relapsed), seven had ara-C resistant disease (three primary and four relapsed patients). Five of the seven patients had a very low dCyd kinase and normal dCyd deaminase activity, whereas the other two had a normal dCyd kinase and an increased dCyd deaminase activity.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009700 Nucleoside Deaminases Catalyze the hydrolysis of nucleosides with the elimination of ammonia. Deaminases, Nucleoside
D010770 Phosphotransferases A rather large group of enzymes comprising not only those transferring phosphate but also diphosphate, nucleotidyl residues, and others. These have also been subdivided according to the acceptor group. (From Enzyme Nomenclature, 1992) EC 2.7. Kinases,Phosphotransferase,Phosphotransferases, ATP,Transphosphorylase,Transphosphorylases,Kinase,ATP Phosphotransferases
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D003842 Deoxycytidine Kinase An enzyme that catalyzes reversibly the phosphorylation of deoxycytidine with the formation of a nucleoside diphosphate and deoxycytidine monophosphate. Cytosine arabinoside can also act as an acceptor. All natural nucleoside triphosphates, except deoxycytidine triphosphate, can act as donors. The enzyme is induced by some viruses, particularly the herpes simplex virus (HERPESVIRUS HOMINIS). EC 2.7.1.74. Kinase, Deoxycytidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
January 1979, Cancer treatment reports,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
January 1978, Medical and pediatric oncology,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
November 1992, Leukemia,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
January 1982, Medical and pediatric oncology,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
May 1994, Leukemia,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
April 1989, The American journal of medicine,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
February 1993, Leukemia & lymphoma,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
June 1996, Leukemia & lymphoma,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
August 1974, Cancer,
L P Colly, and W G Peters, and D Richel, and M W Arentsen-Honders, and C W Starrenburg, and R Willemze
June 1987, Seminars in oncology,
Copied contents to your clipboard!